Asset Management Group Inc. Acquires 15,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Asset Management Group Inc. grew its stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 130.7% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 26,480 shares of the company’s stock after purchasing an additional 15,000 shares during the period. Asset Management Group Inc.’s holdings in Xeris Biopharma were worth $60,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in XERS. Invenomic Capital Management LP bought a new position in Xeris Biopharma during the 4th quarter valued at $1,336,000. Vanguard Group Inc. boosted its holdings in Xeris Biopharma by 7.3% during the first quarter. Vanguard Group Inc. now owns 7,606,242 shares of the company’s stock worth $16,810,000 after purchasing an additional 519,897 shares during the last quarter. NEA Management Company LLC purchased a new position in Xeris Biopharma during the first quarter worth about $926,000. Renaissance Technologies LLC boosted its stake in Xeris Biopharma by 33.9% in the second quarter. Renaissance Technologies LLC now owns 1,351,640 shares of the company’s stock valued at $3,041,000 after acquiring an additional 342,300 shares during the last quarter. Finally, Rosalind Advisors Inc. grew its position in shares of Xeris Biopharma by 10.6% during the 2nd quarter. Rosalind Advisors Inc. now owns 3,120,170 shares of the company’s stock valued at $7,020,000 after acquiring an additional 300,000 shares during the period. 42.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price objective on shares of Xeris Biopharma in a report on Thursday, August 15th.

Xeris Biopharma Price Performance

Shares of XERS opened at $2.93 on Friday. The firm’s 50 day simple moving average is $2.61 and its 200 day simple moving average is $2.26. The company has a market capitalization of $434.39 million, a P/E ratio of -6.23 and a beta of 2.76. Xeris Biopharma Holdings, Inc. has a 1-year low of $1.46 and a 1-year high of $3.26.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, August 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.01. The company had revenue of $48.07 million during the quarter, compared to analyst estimates of $46.80 million. Xeris Biopharma had a negative net margin of 32.83% and a negative return on equity of 16,662.63%. During the same period in the previous year, the business earned ($0.14) earnings per share. On average, equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.4 earnings per share for the current year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.